Filtered By:
Condition: Spinal Muscular Atrophy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 31 results found since Jan 2013.
Positive Phase III results for Roche ’s OCREVUS (ocrelizumab) twice a year, 10-minute subcutaneous injection in patients with multiple sclerosis
Phase III OCARINA II trial met primary and secondary endpointsOCREVUS twice a year, 10-minute injection has the potential to further improve the treatment experience and expand OCREVUS usage in MS centres with IV capacity limitations or without IV infrastructureOCREVUS remains the first and only therapy approved for both RMS and PPMS, and more than 300,000 people have been treated globallyBasel, 13 July 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Phase III OCARINA II trial evaluating OCREVUS ® (ocrelizumab) as a twice a year 10-minute subcutaneous injection met its primary and secondary endpoints in...
Source: Roche Media News - July 13, 2023 Category: Pharmaceuticals Source Type: news
Roche ’s BTK inhibitor fenebrutinib significantly reduced brain lesions in people with relapsing forms of multiple sclerosis
Fenebrutinib is an investigational, potent and highly selective oralBruton ’s tyrosine kinase (BTK) inhibitor, the only reversible BTK inhibitor currently in Phase III multiple sclerosis (MS) trialsPhase II study met its primary and secondary endpoints by reducing the total number of new gadolinium-enhancing T1 brain lesions and significantly reducing the total number of new or enlarging T2 brain lesions compared to placeboThe safety profile offenebrutinib was consistent with previous and ongoing clinical trials across more than 2,400 people to dateBasel, 17 May 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today p...
Source: Roche Media News - May 17, 2023 Category: Pharmaceuticals Source Type: news
Peripherally delivered Adeno-associated viral vectors for spinal cord injury repair
In conclusion, in the future, minimally invasive administration of AAVs may improve recovery after SCI with minimal side effects.PMID:34896114 | DOI:10.1016/j.expneurol.2021.113945
Source: Experimental Neurology - December 13, 2021 Category: Neurology Authors: Jared D Sydney-Smith Aline B Spejo Philippa M Warren Lawrence D F Moon Source Type: research
Repurposing Vorinostat for the Treatment of Disorders Affecting Brain
AbstractBased on the findings in recent years, we summarize the therapeutic potential of vorinostat (VOR), the first approved histone deacetylase (HDAC) inhibitor, in disorders of brain, and strategies to improve drug efficacy and reduce side effects. Scientific evidences provide a strong case for the therapeutic utility of VOR in various disorders affecting brain, including stroke, Alzheimer ’s disease, frontotemporal dementia, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, spinal muscular atrophy, X‐linked adrenoleukodystrophy, epilepsy, Niemann-Pick type C disease, and neuropsychiatric dis...
Source: NeuroMolecular Medicine - December 1, 2021 Category: Neurology Source Type: research
Gene Therapy Approach with an Emphasis on Growth Factors: Theoretical and Clinical Outcomes in Neurodegenerative Diseases
This article mainly focuses on the delivering modes of genetic materials in the CNS, which includes viral and non-viral vectors and their application in gene therapy. Despite the many clinical trials conducted so far, data have shown disappointing outcomes. The efforts done to improve outcomes, efficacy, and safety in the identification of targets in various neurological disorders are also discussed here. Adapting gene therapy as a new therapeutic approach for treating neurological disorders seems to be promising, with early detection and delivery of therapy before the neuron is lost, helping a lot the development of new t...
Source: Molecular Medicine - October 16, 2021 Category: Molecular Biology Authors: Della Grace Thomas Parambi Khalid Saad Alharbi Rajesh Kumar Seetha Harilal Gaber El-Saber Batiha Nat ália Cruz-Martins Omnia Magdy Arafa Musa Dibya Sundar Panda Bijo Mathew Source Type: research
Repurposing Vorinostat for the Treatment of Disorders Affecting Brain
AbstractBased on the findings in recent years, we summarize the therapeutic potential of vorinostat (VOR), the first approved histone deacetylase (HDAC) inhibitor, in disorders of brain, and strategies to improve drug efficacy and reduce side effects. Scientific evidences provide a strong case for the therapeutic utility of VOR in various disorders affecting brain, including stroke, Alzheimer ’s disease, frontotemporal dementia, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, spinal muscular atrophy, X‐linked adrenoleukodystrophy, epilepsy, Niemann-Pick type C disease, and neuropsychiatric dis...
Source: NeuroMolecular Medicine - May 4, 2021 Category: Neurology Source Type: research
Non-invasive assessment of motor unit activation in relation to motor neuron level and lesion location in stroke and spinal muscular atrophy
The results suggest, that for stroke, information from the brain is modified thereby resulting in motor units firing at their natural frequency. Thus, high spatial resolution electromyography and the chosen parameters facilitate non-invasive, objective differentiation and analysis of the activation patterns of motor units in neuromuscular disorders.
Source: Clinical Biomechanics - May 26, 2020 Category: Orthopaedics Authors: Sybele E. Williams, Kathrin C. Koch, Catherine Disselhorst-Klug Source Type: research
